Biomedical HIV Prevention Trials: Results, milestones and more

JANUARY 2019

Vaginal ring

Oral PrEP

Long-acting injectable

JANUARY 2020

Antibody

Preventive HIV vaccine

PrEP and vaccine

JANUARY 2021

EMA regulatory opinion

Submission to the US Food and Drug Administration (FDA)

Submission to the South African Health Products Regulatory Authority (SAHPRA)

F/TAF (DISCOVER—MSM/TG WOMEN)

MK-8591/Islatravir (NCT04003103)*

May 2020: Blinded, randomized portion of the trial stopped early for efficacy. Participants in both arms of the study will be offered CAB LA

JANUARY 2022

F/TAF or F/TDF (PrEPVacc)

DNA-MVA-env or DNA-env with F/TAF or F/TDF (PrEPVacc)